KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Non Operating Income: 2018-2025

Historic Non Operating Income for Esperion Therapeutics (ESPR) over the last 7 years, with Sep 2025 value amounting to $677,000.

  • Esperion Therapeutics' Non Operating Income fell 57.26% to $677,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.6 million, marking a year-over-year decrease of 54.12%. This contributed to the annual value of $8.0 million for FY2024, which is 51.62% up from last year.
  • According to the latest figures from Q3 2025, Esperion Therapeutics' Non Operating Income is $677,000, which was up 1.65% from $666,000 recorded in Q2 2025.
  • In the past 5 years, Esperion Therapeutics' Non Operating Income registered a high of $3.9 million during Q4 2021, and its lowest value of $9,000 during Q2 2021.
  • Over the past 3 years, Esperion Therapeutics' median Non Operating Income value was $1.3 million (recorded in 2023), while the average stood at $1.4 million.
  • Data for Esperion Therapeutics' Non Operating Income shows a peak YoY increase of 16,312.50% (in 2021) and a maximum YoY decrease of 96.20% (in 2021) over the last 5 years.
  • Over the past 5 years, Esperion Therapeutics' Non Operating Income (Quarterly) stood at $3.9 million in 2021, then tumbled by 65.60% to $1.4 million in 2022, then declined by 20.30% to $1.1 million in 2023, then rose by 11.76% to $1.2 million in 2024, then tumbled by 57.26% to $677,000 in 2025.
  • Its last three reported values are $677,000 in Q3 2025, $666,000 for Q2 2025, and $1.1 million during Q1 2025.